Pfizer’s RSV Vaccine Gets FDA Approval

June 1, 2023

The US Food and Drug Administration (FDA) has given approval for the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in older adults. The move comes shortly after the agency approved another RSV vaccine from GSK. This sets up a marketplace standoff between the two, competing over a market that’s estimated at $17 billion.

According to Andrew Dunn, “RSV, or respiratory syncytial virus, is one of the most common viruses in the world, and these are the first-ever approved vaccines after several decades of attempts. The Pfizer and GSK programs both build on a research breakthrough about a key viral protein made around a decade ago by National Institutes of Health researchers.”

To read more, click here.